hydroxychloroquine has been researched along with Fatigue in 14 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Fatigue: The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Several case reports have highlighted symptomatic hypoglycemia as a serious but uncommon adverse effect of hydroxychloroquine (HCQ) in nondiabetic subjects." | 7.96 | Hypoglycemia Induced by Hydroxychloroquine Sulfate in a Patient Treated for Connective Tissue Disease Without Diabetes Mellitus. ( Dai, Y; Lin, G; Shi, D, 2020) |
| "Hydroxychloroquine (HCQ) enhances the anti-cancer activity of the histone deacetylase inhibitor, vorinostat (VOR), in pre-clinical models and early phase clinical studies of metastatic colorectal cancer (mCRC)." | 7.83 | Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer. ( Curiel, T; Goros, M; Hurez, V; Mahalingam, D; Michalek, J; Nawrocki, ST; Patel, S; Sarantopoulos, J, 2016) |
| "To evaluate the efficacy of hydroxychloroquine for the main symptoms of primary Sjögren syndrome: dryness, pain, and fatigue." | 5.19 | Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. ( Batouche, D; Benessiano, J; Devauchelle-Pensec, V; Dubost, JJ; Furlan, V; Goeb, V; Gottenberg, JE; Hatron, P; Hayem, G; Larroche, C; Le Guern, V; Mariette, X; Morel, J; Perdriger, A; Perrodeau, E; Puéchal, X; Ravaud, P; Rist, S; Saraux, A; Sene, D; Seror, R; Sibilia, J; Zarnitsky, C, 2014) |
| "Several case reports have highlighted symptomatic hypoglycemia as a serious but uncommon adverse effect of hydroxychloroquine (HCQ) in nondiabetic subjects." | 3.96 | Hypoglycemia Induced by Hydroxychloroquine Sulfate in a Patient Treated for Connective Tissue Disease Without Diabetes Mellitus. ( Dai, Y; Lin, G; Shi, D, 2020) |
| "Hydroxychloroquine (HCQ) enhances the anti-cancer activity of the histone deacetylase inhibitor, vorinostat (VOR), in pre-clinical models and early phase clinical studies of metastatic colorectal cancer (mCRC)." | 3.83 | Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer. ( Curiel, T; Goros, M; Hurez, V; Mahalingam, D; Michalek, J; Nawrocki, ST; Patel, S; Sarantopoulos, J, 2016) |
| "Fatigue was quantified using a 0-10 visual analogue scale (VAS)." | 1.35 | Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. ( Aguirre, C; Egurbide, MV; Martinez-Berriotxoa, A; Olivares, N; Ruiz-Irastorza, G, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 6 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, K | 1 |
| Coles, TM | 1 |
| Voils, CI | 1 |
| Anderson, DR | 1 |
| Eudy, AM | 1 |
| Sadun, RE | 1 |
| Rogers, JL | 1 |
| Criscione-Schreiber, LG | 1 |
| Doss, J | 1 |
| Maheswaranathan, M | 1 |
| Clowse, MEB | 1 |
| Basheer, A | 1 |
| Khan, EA | 1 |
| Hashmi, T | 1 |
| Khan, RA | 1 |
| Ahmad, A | 1 |
| Bartiromo, M | 1 |
| Borchi, B | 1 |
| Botta, A | 1 |
| Bagalà, A | 1 |
| Lugli, G | 1 |
| Tilli, M | 1 |
| Cavallo, A | 1 |
| Xhaferi, B | 1 |
| Cutruzzulà, R | 1 |
| Vaglio, A | 1 |
| Bresci, S | 1 |
| Larti, A | 1 |
| Bartoloni, A | 1 |
| Cirami, C | 1 |
| Aminian, A | 1 |
| Kermansaravi, M | 1 |
| Azizi, S | 1 |
| Alibeigi, P | 1 |
| Safamanesh, S | 1 |
| Mousavimaleki, A | 1 |
| Rezaei, MT | 1 |
| Faridi, M | 1 |
| Mokhber, S | 1 |
| Pazouki, A | 1 |
| Safari, S | 1 |
| Dai, Y | 1 |
| Lin, G | 1 |
| Shi, D | 1 |
| Bozzalla Cassione, E | 1 |
| Zanframundo, G | 1 |
| Biglia, A | 1 |
| Codullo, V | 1 |
| Montecucco, C | 1 |
| Cavagna, L | 1 |
| Mondal, R | 1 |
| Ganguly, U | 1 |
| Deb, S | 1 |
| Shome, G | 1 |
| Pramanik, S | 1 |
| Bandyopadhyay, D | 1 |
| Lahiri, D | 1 |
| Demarchi, J | 1 |
| Papasidero, S | 1 |
| Medina, MA | 1 |
| Klajn, D | 1 |
| Chaparro Del Moral, R | 1 |
| Rillo, O | 1 |
| Martiré, V | 1 |
| Crespo, G | 1 |
| Secco, A | 1 |
| Catalan Pellet, A | 1 |
| Amitrano, C | 1 |
| Crow, C | 1 |
| Asnal, C | 1 |
| Pucci, P | 1 |
| Caeiro, F | 1 |
| Benzanquen, N | 1 |
| Pirola, JP | 1 |
| Mayer, M | 1 |
| Zazzetti, F | 1 |
| Velez, S | 1 |
| Barreira, J | 1 |
| Tamborenea, N | 1 |
| Santiago, L | 1 |
| Raiti, L | 1 |
| Gottenberg, JE | 1 |
| Ravaud, P | 1 |
| Puéchal, X | 1 |
| Le Guern, V | 1 |
| Sibilia, J | 1 |
| Goeb, V | 1 |
| Larroche, C | 1 |
| Dubost, JJ | 1 |
| Rist, S | 1 |
| Saraux, A | 1 |
| Devauchelle-Pensec, V | 1 |
| Morel, J | 1 |
| Hayem, G | 1 |
| Hatron, P | 1 |
| Perdriger, A | 1 |
| Sene, D | 1 |
| Zarnitsky, C | 1 |
| Batouche, D | 1 |
| Furlan, V | 1 |
| Benessiano, J | 1 |
| Perrodeau, E | 1 |
| Seror, R | 1 |
| Mariette, X | 1 |
| Jones, DW | 1 |
| Wright, D | 1 |
| Jankowski, TA | 1 |
| Changcharoen, B | 1 |
| Bolger, DT | 1 |
| Vivino, FB | 1 |
| Carsons, SE | 1 |
| Foulks, G | 1 |
| Daniels, TE | 1 |
| Parke, A | 1 |
| Brennan, MT | 1 |
| Forstot, SL | 1 |
| Scofield, RH | 1 |
| Hammitt, KM | 1 |
| Patel, S | 1 |
| Hurez, V | 1 |
| Nawrocki, ST | 1 |
| Goros, M | 1 |
| Michalek, J | 1 |
| Sarantopoulos, J | 1 |
| Curiel, T | 1 |
| Mahalingam, D | 1 |
| Ruiz-Irastorza, G | 1 |
| Egurbide, MV | 1 |
| Olivares, N | 1 |
| Martinez-Berriotxoa, A | 1 |
| Aguirre, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Incidence of COVID-19 Test Conversion in Post-surgical Patients[NCT04392323] | 111 participants (Actual) | Interventional | 2020-05-13 | Completed | |||
| Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography.[NCT02874287] | Phase 4 | 35 participants (Actual) | Interventional | 2017-10-08 | Completed | ||
| Randomized, Double-blind, Placebo-controlled Trial of Hydroxychloroquine in Primary Sjögren's Syndrome[NCT00632866] | Phase 3 | 120 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for hydroxychloroquine and Fatigue
| Article | Year |
|---|---|
Meningoencephalitis associated with COVID-19: a systematic review.
Topics: Adult; Aged; Antiviral Agents; Azithromycin; Confusion; Cough; COVID-19; COVID-19 Drug Treatment; Dy | 2021 |
Clinical inquiry. What treatments relieve arthritis and fatigue associated with systemic lupus erythematosus?
Topics: Antirheumatic Agents; Arthritis; Disease Management; Exercise Therapy; Fatigue; Fish Oils; Humans; H | 2014 |
New Treatment Guidelines for Sjögren's Disease.
Topics: Antirheumatic Agents; Biological Products; Cariostatic Agents; Cost of Illness; Delphi Technique; De | 2016 |
1 trial available for hydroxychloroquine and Fatigue
| Article | Year |
|---|---|
Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial.
Topics: Adult; Aged; Double-Blind Method; Enzyme Inhibitors; Fatigue; Female; Humans; Hydroxychloroquine; Ma | 2014 |
Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial.
Topics: Adult; Aged; Double-Blind Method; Enzyme Inhibitors; Fatigue; Female; Humans; Hydroxychloroquine; Ma | 2014 |
Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial.
Topics: Adult; Aged; Double-Blind Method; Enzyme Inhibitors; Fatigue; Female; Humans; Hydroxychloroquine; Ma | 2014 |
Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial.
Topics: Adult; Aged; Double-Blind Method; Enzyme Inhibitors; Fatigue; Female; Humans; Hydroxychloroquine; Ma | 2014 |
10 other studies available for hydroxychloroquine and Fatigue
| Article | Year |
|---|---|
Development and Initial Validation of a Systemic Lupus Erythematosus-Specific Measure of the Extent of and Reasons for Medication Nonadherence.
Topics: Adult; Fatigue; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Medication | 2022 |
Recurrent aseptic meningitis: A rare clinical presentation of Sjogren's syndrome.
Topics: Antibodies, Antinuclear; Antirheumatic Agents; Fatigue; Female; Glucocorticoids; Humans; Hydroxychlo | 2019 |
Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19).
Topics: Adult; Antiviral Agents; Betacoronavirus; C-Reactive Protein; Ciliopathies; Cobicistat; Common Cold; | 2020 |
Bariatric Surgical Practice During the Initial Phase of COVID-19 Outbreak.
Topics: Adult; Anti-Retroviral Agents; Betacoronavirus; Coronavirus Infections; Cough; COVID-19; Dyspnea; Fa | 2020 |
Hypoglycemia Induced by Hydroxychloroquine Sulfate in a Patient Treated for Connective Tissue Disease Without Diabetes Mellitus.
Topics: Adult; Antirheumatic Agents; Blood Glucose; Connective Tissue Diseases; Dizziness; Fatigue; Female; | 2020 |
COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Azathioprine; Betacoronavirus; Clinical Labora | 2020 |
Primary Sjögren's syndrome: Extraglandular manifestations and hydroxychloroquine therapy.
Topics: Adult; Antirheumatic Agents; Fatigue; Female; Humans; Hydroxychloroquine; Hypergammaglobulinemia; In | 2017 |
Thrombotic thrombocytopenic purpura as an initial presentation of systemic lupus erythematosus with acquired ADAMTS 13 antibody.
Topics: ADAM Proteins; ADAMTS13 Protein; Adult; Anemia, Hemolytic; Autoantibodies; Fatigue; Female; Headache | 2015 |
Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Color | 2016 |
Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences.
Topics: Adult; Age Factors; Antirheumatic Agents; Calcifediol; Cross-Sectional Studies; Fatigue; Female; Hum | 2008 |